Bowen, James D. http://orcid.org/0000-0002-4258-250X
Stulc, Jessica
Hunter, Samuel F. http://orcid.org/0000-0002-0542-1176
Chen, Hailu
Lewin, James B. http://orcid.org/0000-0002-2352-9113
Scaramozza, Matthew
Bozin, Ivan http://orcid.org/0009-0008-2205-4233
Then Bergh, Florian
Clinical trials referenced in this document:
Documents that mention this clinical trial
Diroximel Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study
https://doi.org/10.1007/s12325-024-02901-1
Funding for this research was provided by:
Biogen
Article History
Received: 8 March 2024
Accepted: 14 May 2024
First Online: 15 June 2024
Declarations
:
: James D. Bowen: speaker/consulting/advisory fees from Alexion, Alkermes, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, and TG Therapeutics; holds stock in Amgen; research support from Alexion, Alkermes, Biogen, Celgene, Genzyme, Genentech, Novartis, and TG Therapeutics. Jessica Stulc: advisory/data safety monitoring boards for EMD Serono; speaker bureaus for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, and Sanofi; research support from Biogen, EMD Serono, Genentech, Novartis, Sanofi, and TG Therapeutics. Samuel F. Hunter: received consulting fees from Alexion, Biogen, BMS, Genentech, Horizon, Janssen, Sanofi, and Serono; contracted research for Anokion, Atara, Biogen, Genentech, Janssen, and Sanofi; and served on speaker bureaus for Biogen, BMS, EMD Serono, Horizon, and Janssen. Hailu Chen: employee of and held stock/stock options in Biogen at the time of this work; current employee of and holds stock/stock options in Alkermes. James B. Lewin, Matthew Scaramozza, and Ivan Bozin: employees of Biogen and may hold stock in the company. Florian Then Bergh: research support and travel grants, through his institution, from the German Science Fund (DFG), German Federal Ministry of Education and Science (BMBF), Bayer-Schering, Merck, Novartis, Pfizer, Roche, Sanofi, and Teva and speaker fees from and advisory boards for Actelion, Alexion, Bayer, Biogen, CSL Behring, Fresenius, Horizon, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva.
: EVOLVE-MS-1 was approved by local and central ethics committees and conducted in accordance with International Council on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki []. All patients provided written, informed consent. Ethical approval was not applicable for this analysis as data were based on existing outputs from the EVOLVE-MS-1 study.